<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922284</url>
  </required_header>
  <id_info>
    <org_study_id>CRO2059</org_study_id>
    <secondary_id>2012-003277-26</secondary_id>
    <nct_id>NCT01922284</nct_id>
  </id_info>
  <brief_title>Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses</brief_title>
  <acronym>UKHVCSpoke003</acronym>
  <official_title>A Phase I Clinical Trial Investigating Immunisation Strategies Using DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      UKHVC Spoke 003 is a randomised Phase I, two centre study which will explore the impact of
      shortening a vaccination regimen using deoxyribonucleic acid (DNA) (CN54ENV and ZM96GPN),
      Modified Vaccinia Ankara - C (MVA-C) and CN54rgp140 adjuvanted with glucopyranosyl lipid A
      adjuvant - aqueous form (GLA-AF). The study population will be 40 healthy male and female
      volunteers 18 to 45 years old who are at low risk of HIV infection are to be recruited.

      Study participants will be immunised with trial immunogens:

        -  8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone
           and one plasmid encoding gp140 env derived from clade C 97CN54

        -  1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins
           derived from clade-C 97CN54

        -  100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54

        -  5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant

      All immunisations will be administered by the intramuscular route (IM). CN54gp140 and GLA
      will be mixed together before administration, and immunogens will be delivered in combination
      regimens
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I study exploring the safety and potency of five HIV vaccines in healthy
      volunteers. The main aim is to see whether three of the five vaccines can be given together
      rather than one after the other, in five rather than seven sets of vaccinations and a course
      shortened by eight weeks. All volunteers will receive three injections of the first two
      vaccines (DNA plasmids) and half will be randomly assigned to receive two injections each of
      the second (MVA-C) and subsequent vaccines (CN54rgp140 mixed with GLA-AF) during the same
      visit or two injections of the MVA-C followed by two of CN54rgp140 mixed with GLA-AF.

      The investigators are interested in ensuring that the vaccines are safe and also that the
      immune responses in the two groups of volunteers are similar. The three vaccines have all
      been shown to stimulate the immune response to specific parts of the HIV virus and none are
      infectious. The first vaccine consists of two DNA plasmids. When injected into muscle cells
      small parts of the HIV virus which are encoded by the DNA are produced and these are then
      recognised by the immune system. The second vaccine MVAC, is derived from vaccinia virus
      which has been modified so that it cannot divide. The virus (Modified Vaccinia Ankara (MVA))
      actually expresses the same portions of HIV as the DNA and results in amplification of the
      responses seen. The third vaccine is a synthetically produced component of the HIV viral
      outer coat and it will be administered with an additive which has been shown to greatly
      enhance particular types of immune response which have recently been shown to play a role in
      protection against infection
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of antibody response</measure>
    <time_frame>Four weeks after final immunisation</time_frame>
    <description>Magnitude (reciprocal mean endpoint titre and concentration) of systemic Immunoglobulin G (IgG) binding antibody responses to CN54rgp140 measured four weeks after the final immunisation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Every four weeks up to 32 weeks</time_frame>
    <description>Grade 3 or above local solicited adverse event Grade 3 or above systemic clinical and laboratory solicited adverse event Any grade of adverse event that results in a clinical decision to discontinue further immunisations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of neutralising antibody (Nab) responses</measure>
    <time_frame>Four weeks after the final immunisation</time_frame>
    <description>Confirmation of specific investigations will be provided at a later date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of T-cell and B-cell responses</measure>
    <time_frame>Four weeks after the final immunisation</time_frame>
    <description>Confirmation of specific investigations will be provided at a later date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of mucosal IgG and IgA antibody responses</measure>
    <time_frame>Four weeks after the final immunisation</time_frame>
    <description>Confirmation of specific investigations will be provided at a later date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of antibody-dependent cell-mediated cytotoxicity or Antibody-dependent cell-mediated viral inhibition</measure>
    <time_frame>From first immunisation</time_frame>
    <description>Confirmation of specific investigations will be provided at a later date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of systemic Immunoglobulin A (IgA) binding antibody responses</measure>
    <time_frame>Four weeks after the final immunisation</time_frame>
    <description>Confirmation of specific investigations will be provided at a later date.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Group 1 - Combination arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20.
At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Non-combination arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28.
At weeks 16 &amp; 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA</intervention_name>
    <description>8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54</description>
    <arm_group_label>Group 1 - Combination arm</arm_group_label>
    <arm_group_label>Group 2 - Non-combination arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-C</intervention_name>
    <description>1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54</description>
    <arm_group_label>Group 1 - Combination arm</arm_group_label>
    <arm_group_label>Group 2 - Non-combination arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CN54rgp140</intervention_name>
    <description>100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54</description>
    <arm_group_label>Group 1 - Combination arm</arm_group_label>
    <arm_group_label>Group 2 - Non-combination arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLA-AF</intervention_name>
    <description>5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant</description>
    <arm_group_label>Group 1 - Combination arm</arm_group_label>
    <arm_group_label>Group 2 - Non-combination arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Man or woman aged between 18 and 45 years on the day of screening

          2. Available for follow-up for the duration of the study (up to ~10 months from
             enrolment)

          3. At low risk of HIV and willing to remain so for the duration of the study defined as:

               -  no history of injecting drug use in the previous ten years

               -  no gonorrhoea or syphilis in the last six months

               -  no high risk partner (e.g. injecting drug use, HIV positive partner) either
                  currently or within the past six months

               -  no unprotected anal intercourse in the last six months, outside a relationship
                  with a regular partner known to be HIV negative

               -  no unprotected vaginal intercourse in the last six months outside a relationship
                  with a regular known/presumed HIV negative partner

          4. Willing to undergo an HIV test

          5. Willing to undergo a genital infection screen if indicated by sexual history

          6. If heterosexually active female, using an effective method of contraception with
             partner other than an IUCD/IUS (combined oral contraceptive pill; injectable or
             implanted contraceptive; consistent record with condoms if using these; physiological
             or anatomical sterility in self or partner) from 14 days prior to the first
             vaccination until 4 months after the last, and willing to undergo urine pregnancy
             tests prior to each vaccination

          7. If heterosexually active male, using an effective method of contraception with their
             partner from the first day of vaccination until 4 months after the last vaccination

          8. Agree to abstain from donating blood for three months after the end of their
             participation in the trial, or longer if necessary

          9. Registered with a general practitioner (GP) for at least the past three months

         10. Satisfactory response received from GP before randomisation

         11. Willing and able to give written informed consent

        Exclusion Criteria:

          1. Pregnant or lactating

          2. Presence of an IUCD (intrauterine contraceptive device)/IUS (intrauterine system)

          3. Clinically relevant abnormality on history or examination including

               -  history of grand-mal epilepsy, seizure disorder or any history of prior seizure

               -  severe eczema

               -  liver disease with inadequate hepatic function

               -  any skin condition which may interfere with the trial assessment on the injection
                  site

               -  haematological, metabolic, gastrointestinal or cardio-pulmonary disorders

               -  uncontrolled infection; toxic shock syndrome; autoimmune disease,
                  immunodeficiency or use of immunosuppressives in preceding 3 months

          4. Known hypersensitivity to any component of the vaccine formulations used in this
             trial, or have severe or multiple allergies to drugs or pharmaceutical agents

          5. History of severe local or general reaction to vaccination defined as

               1. local: extensive, indurated redness and swelling involving the major
                  circumference of the arm, not resolving within 72 hours

               2. general: fever &gt;= 39.5Â°C within 48 hours; anaphylaxis; bronchospasm; laryngeal
                  oedema; collapse; convulsions or encephalopathy within 72 hours

          6. Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of
             enrolment

          7. Receipt of an experimental vaccine containing HIV antigens at any time in the past

          8. Receipt of blood products or immunoglobin within 4 months of screening

          9. Participation in another trial of a medicinal product, completed less than 30 days
             prior to enrolment

         10. HIV 1 or 2 positive or indeterminate on screening

         11. Positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating
             active syphilis requiring treatment

         12. Grade 1 or above routine laboratory parameters. Hyperbilirubinaemia to be considered
             an exclusion criterion only when confirmed to be conjugated bilirubinaemia

         13. Unable to read and speak English to a fluency level adequate for the full
             comprehension of procedures required in participation and consent.

         14. Unlikely to comply with protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheena McCormack, MSc, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Clinical Scientist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surrey Clinical Research Centre, University of Surrey</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>Greater London</city>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunisation</keyword>
  <keyword>DNA</keyword>
  <keyword>Adverse events</keyword>
  <keyword>MVA-C</keyword>
  <keyword>GLA-AF</keyword>
  <keyword>Antibody</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

